Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis

Murray-Lyon, 1973, Controlled trial of prednisone and azathioprine in active chronic hepatitis, Lancet, 1, 735, 10.1016/S0140-6736(73)92125-9 Soloway, 1972, Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis, Gastroenterology, 63, 820, 10.1016/S0016-5085(19)33223-8 Czaja, 2004, Progressive fibrosis during corticosteroid therapy of autoimmune hepatitis, Hepatology, 39, 1631, 10.1002/hep.20235 Dhaliwal, 2015, Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis, Am J Gastroenterol, 110, 993, 10.1038/ajg.2015.139 Lüth, 2008, Serologic markers compared with liver biopsy for monitoring disease activity in autoimmune hepatitis, J Clin Gastroenterol, 42, 926, 10.1097/MCG.0b013e318154af74 Manns, 2010, Diagnosis and management of autoimmune hepatitis, Hepatology, 51, 2193, 10.1002/hep.23584 Gleeson, 2011, British Society of Gastroenterology (BSG) guidelines for management of autoimmune hepatitis, Gut, 60, 1611, 10.1136/gut.2010.235259 2015, EASL Clinical Practice Guidelines: Autoimmune hepatitis, J Hepatol, 63, 971, 10.1016/j.jhep.2015.06.030 Hartl, 2016, Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis, J Hepatol, 65, 769, 10.1016/j.jhep.2016.05.023 Xu, 2017, Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis, J Gastroenterol Hepatol, 32, 639, 10.1111/jgh.13508 Corpechot, 2012, Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis, Hepatology, 56, 198, 10.1002/hep.25599 Corpechot, 2006, Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC, Hepatology, 43, 1118, 10.1002/hep.21151 Corpechot, 2014, Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis, Gastroenterology, 146, 970, 10.1053/j.gastro.2013.12.030 2009, EASL Clinical Practice Guidelines: Management of cholestatic liver diseases, J Hepatol, 51, 237, 10.1016/j.jhep.2009.04.009 Chapman, 2009, AASLD practice guidelines: diagnosis and management of primary sclerosing cholangitis, Hepatology, 51, 660, 10.1002/hep.23294 Sandrin, 2003, Transient elastography: a new noninvasive method for assessment of hepatic fibrosis, Ultrasound Med Biol, 29, 1705, 10.1016/j.ultrasmedbio.2003.07.001 Helmreich-Becker, 2003, Meyer zum Büschenfelde KH, Lohse AW. Minilaparoscopy in the diagnosis of cirrhosis, Endoscopy, 35, 55, 10.1055/s-2003-36419 Desmet, 1994, Classification of chronic hepatitis: diagnosis, Grading and Staging. Hepatology, 19, 1513, 10.1002/hep.1840190629 Ishak, 1995, Histological grading and staging of chronic hepatitis, J Hepatol, 22, 696, 10.1016/0168-8278(95)80226-6 Muratori, 2009, Autoimmune hepatitis in Italy: the Bologna experience, J Hepatol, 50, 1210, 10.1016/j.jhep.2009.01.020 Orlando, 1990, Laparoscopy and liver biopsy: further evidence that the two procedures improve the diagnosis of liver cirrhosis. A retrospective study of 1,003 consecutive examinations, J Clin Gastroenterol, 12, 47, 10.1097/00004836-199002000-00013 Czaja, 2004, Decreased fibrosis during corticosteroid therapy o autoimmune hepatitis, J Hepatol, 40, 646, 10.1016/j.jhep.2004.01.009 Czaja, 2014, Hepatic inflammation and progressive hepatic fibrosis in chronic liver disease, World J Gastroenterol, 20, 2515, 10.3748/wjg.v20.i10.2515 Czaja, 2014, Review article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis, Aliment Pharmacol Ther, 39, 385, 10.1111/apt.12592 Lohse, 2011, Autoimmune hepatitis, J Hepatol, 55, 171, 10.1016/j.jhep.2010.12.012 Rockey, 2016, Liver fibrosis reversion after suppression of hepatitis B virus, Clin Liver Dis, 20, 667, 10.1016/j.cld.2016.06.003 Hartl, 2015, Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis, J Hepatol, 62, 642, 10.1016/j.jhep.2014.10.018